Discontinued — last reported Q3 '25
E2609 and BAN2401 — Expense incurred by the collaboration
Biogen E2609 and BAN2401 — Expense incurred by the collaboration increased by 7.4% to $176.80M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 7.4%, from $164.60M to $176.80M. Over 2 years (FY 2021 to FY 2023), E2609 and BAN2401 — Expense incurred by the collaboration shows an upward trend with a 234.5% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase reflects higher overall operational activity or scaling of the collaborative project, which may precede future commercialization efforts.
Detailed definition
This metric captures the total operational expenses generated by a collaborative entity or project before any allocation...
Peer comparison
Similar to 'total program costs' or 'gross collaborative project expenses' reported by pharmaceutical companies in their segment disclosures for joint ventures.
biib_segment_e2609_and_ban2401_expense_incurred_by_the_collaborationHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.30M | $5.60M | $11.60M | $15.90M | $23.40M | $29.00M | $36.30M | $10.50M | $17.10M | $163.40M | $113.40M | $173.90M | $137.70M | $164.60M | $176.80M |
| QoQ Change | — | +30.2% | +107.1% | +37.1% | +47.2% | +23.9% | +25.2% | -71.1% | +62.9% | +855.6% | -30.6% | +53.4% | -20.8% | +19.5% | +7.4% |
| YoY Change | — | — | — | — | +444.2% | +417.9% | +212.9% | -34.0% | -26.9% | +463.4% | +212.4% | >999% | +705.3% | +0.7% | +7.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's e2609 and ban2401 — expense incurred by the collaboration?
- Biogen (BIIB) reported e2609 and ban2401 — expense incurred by the collaboration of $176.80M in Q3 2025.
- How has Biogen's e2609 and ban2401 — expense incurred by the collaboration changed year-over-year?
- Biogen's e2609 and ban2401 — expense incurred by the collaboration increased by 7.4% year-over-year, from $164.60M to $176.80M.
- What is the long-term trend for Biogen's e2609 and ban2401 — expense incurred by the collaboration?
- Over 2 years (2021 to 2023), Biogen's e2609 and ban2401 — expense incurred by the collaboration has grown at a 234.5% compound annual growth rate (CAGR), from $27.20M to $304.40M.
- What does e2609 and ban2401 — expense incurred by the collaboration mean?
- The total operational costs generated by a collaborative project before accounting for individual partner shares.